Trial Profile
A prospective cohort study of Dolutegravir and Lamivudine assessing efficacy and safety in HIV-infected HAART-treated Patients : DOLULAM Pilot Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2017
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms DOLULAM
- 01 Oct 2017 Results of virological substudy assessing the prevalence of M184I/V mutations at dual therapy initiation using historical DNA/RNA genotypes and baseline DNA genotype obtained by next-generation sequencing (NGS) published in the Journal of Antimicrobial Chemotherapy
- 26 Jul 2017 96 weeks results from maintenance DOLULAM study presented at the 9th International AIDS Society Conference on HIV Science
- 26 Jul 2017 Results of a substudy assessing the prevalence of M184I/V mutations at time of dual-therapy initiation presented at the 9th International AIDS Society Conference on HIV Science